ReviewInternational journal of molecular sciences2017
Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Modulatory effects of bioactive natural compounds on pruritic pathways: mechanistic basis and therapeutic prospects.Inflammopharmacology · 2025Review
- WISIT vaccines based on IL-31-derived peptides as a novel therapeutic approach for chronic pruritic dermatoses.PloS one · 2025Article
- Potential Aspects of the Use of Cytokines in Atopic Dermatitis.Biomedicines · 2024Review
- GPR15L is an epithelial inflammation-derived pruritogen.Science advances · 2022Article
- Article
- The Pathology of Type 2 Inflammation-Associated Itch in Atopic Dermatitis.Diagnostics (Basel, Switzerland) · 2021Review
- Oncostatin M can sensitize sensory neurons in inflammatory pruritus.Science translational medicine · 2021Article
- Altered Monocytic Phenotypes are Associated with Uraemic Pruritus in Patients Receiving Haemodialysis.Acta dermato-venereologica · 2021Article
- Ovalicin attenuates atopic dermatitis symptoms by inhibiting IL-31 signaling and intracellular calcium influx.Journal of biomedical research · 2021Article
- Effects of Hyperbaric Oxygen Therapy in Children with Severe Atopic Dermatitis.Journal of clinical medicine · 2021Article
- Interleukin-31 as a Clinical Target for Pruritus Treatment.Frontiers in medicine · 2021Review
- Review of Prominent Cytokines as Superior Therapeutic Targets for Moderate-to-Severe Atopic Dermatitis.Cureus · 2020Review
- Antipruritic Effect of Ethyl Acetate Extract fromEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Use of Physcion to Improve Atopic Dermatitis-Like Skin Lesions through Blocking of Thymic Stromal Lymphopoietin.Molecules (Basel, Switzerland) · 2019Article
- Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1.The Journal of dermatology · 2019Review
- Matrine inhibits itching by lowering the activity of calcium channel.Scientific reports · 2018Article
- Pruritus Associated with Targeted Anticancer Therapies and Their Management.Dermatologic clinics · 2018Review
- Pruritus: Progress toward Pathogenesis and Treatment.BioMed research international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Itch is the main chief complaint in patients visiting dermatologic clinics and has the ability to deeply impair life quality. Itch results from activation of cutaneous nerve endings by noxious stimuli such as inflammatory mediators, neurotransmitters and neuropeptides, causing itch signal transduction from peripheral skin, through the spinal cord and thalamus, to the brain cortex. Primarily noninflammatory diseases, such as uremic pruritus, cause itch through certain pruritogens in the skin. In inflammatory skin diseases, atopic dermatitis (AD) is the prototypic disease causing intensive itch by aberrant skin inflammation and epidermal barrier disruption. Recent understanding of disease susceptibility, severity markers, and mechanisms have helped to develop targeted therapy for itch in AD, including monoclonal antibodies against IL-4, IL-13, thymic stromal lymphopoietin (TSLP), IgE and IL-31. Promising effects have been observed in some of them. In this review, we summarized targeted therapies for inflammatory itch in AD and for managing abnormal itch transductions in other common itching skin diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.